vcvibes

Even One Ventures

Emerging manager

Built from this firm's Form D filings. The firm files no SEC adviser report.

HQ
CA

Even One Ventures starts biotechs that aim to make scientific advances rapidly accessible to patients. Its portfolio includes companies working on personalized mRNA cancer vaccines, precision mitochondrial testing, therapies designed from T-cell receptors, matching patients to cancer clinical trials in China, and custodial biobanking of tumor samples. Other portfolio companies focus on biology-matched therapies for immune-mediated conditions, a novel drug for relapsed or refractory multiple myeloma, oncolytic viruses, functional tumor testing, endometriosis profiling, gene editing for inherited disorders, and AI-driven treatment options. General partners include Sid Sijbrandij, Jacob Stern, José Mejía Oneto, and Chris Hubbell.

01 · Says / Does

TagSaysDoes
StagesNot statedNot enough dated deals
SectorsBiotechNot enough dated deals
RegionsNot statedNot enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

FundYearSizeStatus
Even One Ventures Fund I LP

Starts biotechs that make scientific advances rapidly accessible to patients. Builds companies across oncology, immune, women's health, rare disease and longevity, including personalized cancer therapies, diagnostics and gene editing. Inferred from the firm's website and portfolio companies

2026$9.15M (Form D)Raising
Even One Ventures Fund II LP

Starts biotechs that make scientific advances rapidly accessible to patients. Builds companies across oncology, immune, women's health, rare disease and longevity, including personalized cancer therapies, diagnostics and gene editing. Inferred from the firm's website and portfolio companies

2026$20M (Form D)Raising

03 · People across funds

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

  1. https://evenone.ventures
  2. https://evenone.ventures/

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026